Realizing the Potential of Anti–SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management | Infectious Diseases | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Realizing the Potential of Anti–SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Corresponding Author: Rajesh T. Gandhi, MD, Massachusetts General Hospital, Cox 548, Boston, MA 02446 (rgandhi@mgh.harvard.edu).

Published Online: January 14, 2022. doi:10.1001/jama.2021.19994

Conflict of Interest Disclosures: Dr Li reported consulting for AbbVie and Recovery Therapeutics. Dr Gandhi reported previously serving on an advisory board for Merck Scientific.

Funding/Support: This work was supported by the Harvard University Center for AIDS Research (National Institute of Allergy and Infectious Diseases [NIAID] award 5P30AI060354) to Drs Li and Gandhi. Drs Li and Gandhi also received grant funding from the AIDS Clinical Trials Group (National Institutes of Health/NIAID award UM1 AI106701 to Dr Li and award UM1 AI069412-09 to Dr Gandhi).

Role of the Funder/Sponsor: The funding institutions had no role in the preparation, review, or approval of the manuscript or the decision to submit the manuscript for publication.

References
1.
Gandhi  RT , Lynch  JB , Del Rio  C .  Mild or moderate Covid-19.   N Engl J Med. 2020;383(18):1757-1766. doi:10.1056/NEJMcp2009249PubMedGoogle ScholarCrossref
2.
O’Brien  MP , Forleo-Neto  E , Sarkar  N ,  et al; COVID-19 Phase 3 Prevention Trial Team.  Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical trial.   JAMA. Published online January 14, 2022. doi:10.1001/jama.2021.24939Google Scholar
3.
McMahan  K , Yu  J , Mercado  NB ,  et al.  Correlates of protection against SARS-CoV-2 in rhesus macaques.   Nature. 2021;590(7847):630-634. doi:10.1038/s41586-020-03041-6PubMedGoogle ScholarCrossref
4.
Zohar  T , Loos  C , Fischinger  S ,  et al.  Compromised humoral functional evolution tracks with SARS-CoV-2 mortality.   Cell. 2020;183(6):1508-1519. doi:10.1016/j.cell.2020.10.052PubMedGoogle ScholarCrossref
5.
Lucas  C , Klein  J , Sundaram  ME ,  et al; Yale IMPACT Research Team.  Delayed production of neutralizing antibodies correlates with fatal COVID-19.   Nat Med. 2021;27(7):1178-1186. doi:10.1038/s41591-021-01355-0PubMedGoogle ScholarCrossref
6.
Dougan  M , Nirula  A , Azizad  M ,  et al; BLAZE-1 Investigators.  Bamlanivimab plus etesevimab in mild or moderate Covid-19.   N Engl J Med. 2021;385(15):1382-1392. doi:10.1056/NEJMoa2102685PubMedGoogle ScholarCrossref
7.
Weinreich  DM , Sivapalasingam  S , Norton  T ,  et al; Trial Investigators.  REGEN-COV antibody combination and outcomes in outpatients with Covid-19.   N Engl J Med. 2021;384:238-251. doi:10.1056/NEJMoa2035002PubMedGoogle ScholarCrossref
8.
Gupta  A , Gonzalez-Rojas  Y , Juarez  E ,  et al; COMET-ICE Investigators.  Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab.   N Engl J Med. 2021;385(21):1941-1950. doi:10.1056/NEJMoa2107934PubMedGoogle ScholarCrossref
9.
O’Brien  MP , Forleo-Neto  E , Musser  BJ ,  et al; Covid-19 Phase 3 Prevention Trial Team.  Subcutaneous REGEN-COV antibody combination to prevent Covid-19.   N Engl J Med. 2021;385(13):1184-1195. doi:10.1056/NEJMoa2109682PubMedGoogle ScholarCrossref
10.
VanBlargan  LA , Errico  JM , Halfmann  PJ ,  et al.  An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies.   bioRxiv. Preprint posted December 17, 2021. doi:10.1101/2021.12.15.472828Google Scholar
11.
Mlcochova  P , Kemp  SA , Dhar  MS ,  et al; Indian SARS-CoV-2 Genomics Consortium; Genotype to Phenotype Japan Consortium; CITIID-NIHR BioResource COVID-19 Collaboration.  SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion.   Nature. 2021;599:114-119. doi:10.1038/s41586-021-03944-yPubMedGoogle ScholarCrossref
12.
Wang  Y , Chen  R , Hu  F ,  et al.  Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China.   EClinicalMedicine. 2021;40:101129. doi:10.1016/j.eclinm.2021.101129PubMedGoogle Scholar
13.
US Food and Drug Administration. Fact sheet for healthcare providers—Emergency Use Authorization (EUA) of REGEN-COV (casirivimab and imdevimab). Accessed October 31, 2021. https://www.fda.gov/media/145611/download
14.
US Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for Evusheld (tixagevimab co-packaged with cilgavimab). Accessed January 4, 2022. https://www.fda.gov/media/154701/download
15.
ACTIV-3/TICO Bamlanivimab Study Group.  Responses to a neutralizing monoclonal antibody for hospitalized patients with COVID-19 according to baseline antibody and antigen levels: a randomized controlled trial.   Ann Intern Med. Published online December 21, 2021. doi:10.7326/M21-3507PubMedGoogle Scholar
16.
US Food and Drug Administration. Fact sheet for health care providers: Emergency Use Authorization for Paxlovid. Accessed January 4, 2022. https://www.fda.gov/media/155050/download
17.
Jayk Bernal  A , Gomes da Silva  MM , Musungaie  DB ,  et al.  Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients.   N Engl J Med. Published online December 16, 2021. doi:10.1056/NEJMoa2116044PubMedGoogle Scholar
18.
Choudhary  MC , Chew  KW , Deo  R ,  et al.  Emergence of SARS-CoV-2 resistance with monoclonal antibody therapy.   medRxiv. Preprint posted September 15, 2021. doi:10.1101/2021.09.03.21263105Google Scholar
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close